UACA (uveal autoantigen with coiled-coil domains and ankyrin repeats) was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves’ disease. UACA was also later identified as Nucling, an mRNA differentially expressed in F9 embryonal carcinoma cells during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1-pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.
Alternative names for
UACA Antibody include
Uveal autoantigen with coiled-coil domains and ankyrin repea
uveal autoantigen with coiled-coil domains and ankyrin repea
nuclear membrane binding protein antibody,
uveal autoantigen with coiled coil domains and ankyrin repeats antibody.